Loading…
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as ophthalmologists. The company sells its products directly through its sales representatives in Japan, the United States, Germany, Spain, Singapore, Canada, and the United Kingdom, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $239M | $-37M | $-80M | $-40M | -23.4% | -23.7% | 298.1% |
| 2024 | $314M | $-6M | $-20M | $-8M | -5.1% | -2.6% | -194.7% |
| 2023 | $322M | $33M | $21M | $-4M | 5.5% | 13.4% | -46.2% |
| 2022 | $284M | $48M | $40M | $18M | 11.8% | - | - |
| 2021 | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 284.39 | 322.42 | 313.90 | 239.44 |
| Operating Revenue | - | 284.39 | 322.42 | 313.90 | 239.44 |
| Cost Of Revenue | - | 61.01 | 69.76 | 74.32 | 57.02 |
| Gross Profit | - | 223.38 | 252.65 | 239.58 | 182.42 |
| Operating Expense | - | 179.58 | 224.55 | 252.19 | 228.37 |
| Research And Development | - | 35.98 | 40.48 | 45.32 | 40.06 |
| Selling General And Administration | - | 143.60 | 184.08 | 206.88 | 188.31 |
| Total Expenses | - | 240.59 | 294.32 | 326.51 | 285.39 |
| Operating Income | - | 43.80 | 28.10 | -12.61 | -45.95 |
| Total Operating Income As Reported | - | 43.80 | 28.10 | -12.61 | -91.71 |
| EBITDA | - | 48.31 | 33.22 | -5.72 | -37.22 |
| Normalized EBITDA | - | 50.02 | 35.13 | -2.04 | 5.95 |
| EBIT | - | 43.80 | 28.10 | -12.61 | -45.95 |
| Interest Income | - | 2.45 | 6.99 | 5.91 | 4.59 |
| Net Interest Income | - | 2.45 | 6.99 | 5.91 | 4.59 |
| Other Non Operating Income Expenses | - | 1.01 | 0.52 | 1.32 | 2.25 |
| Other Income Expense | - | -0.70 | -1.39 | -2.35 | -40.91 |
| Interest Income Non Operating | - | 2.45 | 6.99 | 5.91 | 4.59 |
| Net Non Operating Interest Income Expense | - | 2.45 | 6.99 | 5.91 | 4.59 |
| Pretax Income | - | 45.55 | 33.70 | -9.05 | -82.26 |
| Tax Provision | - | 5.89 | 12.35 | 11.16 | -1.82 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | -0.22 | -0.70 | -0.77 | -0.95 |
| Net Income Continuous Operations | - | 39.66 | 21.35 | -20.21 | -80.45 |
| Net Income From Continuing And Discontinued Operation | - | 39.66 | 21.35 | -20.21 | -80.45 |
| Net Income From Continuing Operation Net Minority Interest | - | 39.66 | 21.35 | -20.21 | -80.45 |
| Net Income | - | 39.66 | 21.35 | -20.21 | -80.45 |
| Net Income Common Stockholders | - | 39.66 | 21.35 | -20.21 | -80.45 |
| Net Income Including Noncontrolling Interests | - | 39.66 | 21.35 | -20.21 | -80.45 |
| Normalized Income | - | 41.15 | 22.56 | -17.30 | -38.23 |
| Diluted NI Availto Com Stockholders | - | 39.66 | 21.35 | -20.21 | -80.45 |
| Basic Average Shares | - | 47.99 | 48.52 | 49.12 | 49.57 |
| Diluted Average Shares | - | 49.38 | 49.43 | 49.12 | 49.57 |
| Reconciled Depreciation | - | 4.51 | 5.12 | 6.89 | 8.73 |
| Reconciled Cost Of Revenue | - | 61.01 | 69.76 | 74.32 | 57.02 |
| Total Unusual Items | - | -1.71 | -1.91 | -3.68 | -43.16 |
| Total Unusual Items Excluding Goodwill | - | -1.71 | -1.91 | -3.68 | -43.16 |
| Special Income Charges | - | - | 0 | 0 | -45.77 |
| Restructuring And Mergern Acquisition | - | - | 0 | 0 | 45.77 |
| Gain On Sale Of Security | - | -1.71 | -1.91 | -3.68 | 2.60 |
| General And Administrative Expense | - | 54.74 | 72.32 | 89.90 | 85.78 |
| Other Gand A | - | 54.74 | 72.32 | 89.90 | 85.78 |
| Total Other Finance Cost | 0.04 | -2.45 | -6.99 | - | - |
| Selling And Marketing Expense | - | 88.86 | 111.76 | 116.98 | 102.53 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| STAAR Surgical Companythis co. | STAA | $1.5B | -18.48 | 4.32 | -23.4% | -36.86 |
| ArriVent BioPharma, Inc. | AVBP | $1.5B | - | 5.02 | -54.1% | - |
| PROCEPT BioRobotics Corporation | PRCT | $1.5B | -16.08 | 4.20 | -26.1% | -15.56 |
| AnaptysBio, Inc. | ANAB | $1.5B | - | 40.41 | -35.6% | 17.42 |
| Perrigo Company plc | PRGO | $1.5B | -1.04 |
| - |
| - |
| - |
| - |
| - |
| 0.50 |
| -48.6% |
| -5.75 |
| NeoGenomics, Inc. | NEO | $1.5B | -13.63 | 1.76 | -12.9% | -44.52 |
| MBX Biosciences, Inc. | MBX | $1.5B | -16.92 | 3.98 | -23.6% | -14.28 |
| Monte Rosa Therapeutics, Inc. | GLUE | $1.5B | -37.97 | 6.29 | -16.6% | -30.01 |
| Aveanna Healthcare Holdings Inc. | AVAH | $1.4B | 6.42 | 7.40 | 115.3% | 10.26 |
| Peer Median | - | -14.86 | 4.61 | -24.8% | -14.28 | |